Q3 Earnings Estimate for MREO Issued By Lifesci Capital

Key Points

• Lifesci Capital analysts estimate Mereo BioPharma Group will post Q3 2025 earnings of ($0.02) per share, while the full-year consensus estimate is currently at ($0.03) per share.
• The stock has a consensus rating of "Moderate Buy" with a price target of $7.20, though it has recently received both buy and sell ratings from various analysts.
• Mereo BioPharma's shares have traded between a 52-week low of $1.47 and a high of $5.02, with the current market capitalization sitting at approximately $275 million.

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Free Report) - Lifesci Capital issued their Q3 2025 EPS estimates for shares of Mereo BioPharma Group in a research report issued on Tuesday, August 12th. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings per share of ($0.02) for the quarter. The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share. Lifesci Capital also issued estimates for Mereo BioPharma Group's Q4 2025 earnings at ($0.02) EPS.

A number of other brokerages also recently issued reports on MREO. Needham & Company LLC set a $5.00 price objective on shares of Mereo BioPharma Group and gave the stock a "buy" rating in a research report on Thursday, July 10th. Wall Street Zen raised shares of Mereo BioPharma Group from a "sell" rating to a "hold" rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $7.20.

Mereo BioPharma Group Price Performance

Shares of NASDAQ:MREO traded down $0.0450 during trading hours on Thursday, hitting $1.6350. The company's stock had a trading volume of 691,502 shares, compared to its average volume of 1,750,251. Mereo BioPharma Group has a 52 week low of $1.47 and a 52 week high of $5.02. The company has a market capitalization of $259.97 million, a price-to-earnings ratio of -23.36 and a beta of 0.47. The firm's fifty day moving average price is $2.18 and its 200 day moving average price is $2.36.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $7.80 million.

Hedge Funds Weigh In On Mereo BioPharma Group

A number of large investors have recently added to or reduced their stakes in MREO. Goldman Sachs Group Inc. grew its holdings in shares of Mereo BioPharma Group by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company's stock valued at $4,783,000 after purchasing an additional 6,068 shares during the period. Significant Wealth Partners LLC grew its holdings in shares of Mereo BioPharma Group by 61.7% in the second quarter. Significant Wealth Partners LLC now owns 22,261 shares of the company's stock valued at $60,000 after purchasing an additional 8,490 shares during the period. Avanza Fonder AB grew its holdings in shares of Mereo BioPharma Group by 43.5% in the first quarter. Avanza Fonder AB now owns 28,121 shares of the company's stock valued at $67,000 after purchasing an additional 8,521 shares during the period. Graham Capital Management L.P. grew its holdings in shares of Mereo BioPharma Group by 74.7% in the fourth quarter. Graham Capital Management L.P. now owns 22,189 shares of the company's stock valued at $78,000 after purchasing an additional 9,490 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Mereo BioPharma Group by 109.5% in the first quarter. GAMMA Investing LLC now owns 18,855 shares of the company's stock valued at $42,000 after purchasing an additional 9,854 shares during the period. 62.83% of the stock is currently owned by institutional investors and hedge funds.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.